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RATIONALE: Cardiac involvement and hypotension dominate the prognosis of light-chain amyloidosis (AL). Evidence suggests 
that there is also peripheral vascular involvement in AL but its prognostic significance is unknown.
OBJECTIVE: To evaluate vascular dysfunction in patients with AL as a potential future area of intervention, we assessed the 
prognostic utility of flow-mediated dilatation (FMD), a marker of vascular reactivity, which is augmented under conditions of 
hypotension and autonomic dysfunction.
METHODS AND RESULTS: We prospectively evaluated 115 newly diagnosed untreated AL patients in whom FMD was measured. 
FMD in AL patients was significantly higher than age-, sex- and risk factors–matched controls (4.0% versus 2.32%; P=0.006) 
and comparable with control groups at lower cardiovascular risk (P>0.1). Amyloidosis patients presented increased plasma and 
exhaled markers of the NO pathway while their FMD significantly correlated with augmented sustained vasodilatation after 
sympathetic stimulation. Increased FMD (≥4.5%) was associated with early mortality (hazard ratio, 4.36; 95% CI, 1.41–13.5; 
P=0.010) and worse survival (hazard ratio, 2.11; 95% CI, 1.17–3.82; P=0.013), even after adjustment for Mayo stage, nerve 
involvement and low systolic blood pressure. This finding was confirmed in a temporal validation AL cohort (n=55; hazard ratio, 
4.2; 95% CI, 1.45–12.3; P=0.008). FMD provided significant reclassification value over the best prognostic model (continuous 
Net Reclassification Index, 0.61; P=0.001). Finally, better hematologic response was associated with lower posttreatment FMD.
CONCLUSIONS: FMD is relatively increased in AL and independently associated with inferior survival with substantial 
reclassification value. Reactive vasodilation merits further investigation as a novel risk biomarker in AL.
VISUAL OVERVIEW: An online visual overview is available for this article.
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Light-chain amyloidosis (AL) is a systemic lethal disease caused by the accumulation of amyloid fibrils in various tissues and organs and with special predilection for the cardiovascular system.
1 Cardiac amyloid involvement and 
resulting dysfunction is the main cause of death in patients 
with immunoglobulin AL. In addition to cardiac dysfunction, 
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evidence suggests that there is also vascular involvement2 in 
AL; however, its prognostic significance is unknown. Nota-
bly, the presence of low blood pressure (BP)—a common 
manifestation of AL disease and possibly indicative of vas-
cular impairment—identifies a group of patients with poor 
outcome.3 The mechanisms of low BP in AL remain elusive; 
low cardiac output and low oncotic pressure due to hypo-
albuminemia have been implicated. However, autonomic 
dysfunction due to disease-related nerve involvement that 
is manifested as vascular sympathetic denervation and a 
generalized dysfunction in the autonomic control of vascular 
reactivity4 may also be implicated. Simultaneously, with the 
presence of autonomic dysfunction, hypotension is often 
evident in AL possibly because of compensatory mecha-
nisms under investigation.4 This suggests that more sensitive 
hemodynamic markers than resting arterial BP measure-
ment may provide prognostic information at earlier stages 
of the disease and possibly allow more accurate risk strati-
fication. Flow-mediated dilatation (FMD) is a well-validated 
noninvasively acquired research tool and marker of vascular 
reactivity, which is decreased in conditions of endothelial 
dysfunction mainly because of low bioavailability of NO5–8 
but augmented in conditions associated with hypotension 
and sympathetic deactivation such as vasovagal syncope 
and liver cirrhosis.9–12 Interestingly, sympathetic nerve stimu-
lation decreases FMD,13 whereas sympathetic attenuation 
increases FMD.14 We hypothesized that FMD as an estimate 
of vascular reactivity could be an objective marker of abnor-
mal reactive vasodilation in patients with AL and aimed to 
provide proof of concept for this hypothesis. Furthermore, 
we aimed to explore the prognostic and risk reclassification 
value of FMD as a possible novel biomarker in AL.
METHODS
The data that support the findings of this study are available 
from the corresponding authors on reasonable request.
Population and Design
From 2008 to 2014, 115 consecutive, newly diagnosed, 
treatment-naive patients with systemic AL were prospec-
tively included in this study (prospective derivation cohort). All 
patients had biopsy-proven AL and were diagnosed and fol-
lowed in the Department of Clinical Therapeutics, Alexandra 
Hospital, Athens, Greece. Consensus criteria were used for 
the definition and assessment of organ involvement.15 In the 
Nonstandard Abbreviations and Acronyms
AL light-chain amyloidosis
BP blood pressure
CPT cold pressure test
CVD cardiovascular disease
FMD flow-mediated dilatation
HR hazard ratio
hs TnT high-sensitive Troponin T
NRI Net Reclassification Index
NT-proBNP  N-terminal pro-B-type natriuretic 
peptide
NTY 3-nitrotyrosine
Novelty and Significance
What Is Known?
• Cardiac involvement, hypotension, and autonomic dys-
function are associated with poor prognosis in immu-
noglobulin light-chain amyloidosis (AL).
• Flow-mediated dilatation (FMD) of the brachial artery—
a well established noninvasive marker of vascular 
reactivity—is augmented in conditions characterized by 
hypotension or autonomic dysfunction.
• The clinical significance of vascular reactivity in AL is 
unknown.
What New Information Does This Article  
Contribute?
• Vascular reactivity in AL is relatively increased when 
compared with matched controls.
• Vascular reactivity determined by FMD is an indepen-
dent predictor of all-cause mortality in AL.
• Increased FMD improves risk stratification over estab-
lished markers of adverse outcome in AL, including car-
diac involvement, cardiobiomarkers, and hypotension.
• Increased vascular reactivity in AL patients closely cor-
relates with vascular autonomic dysfunction.
In a cohort study, we explored the clinical value of 
FMD as an established marker of vascular reac-
tivity in AL patients. This study shows for the first 
time that reactive vasodilatation is augmented in 
AL, is associated with vascular autonomic dysfunc-
tion, independently predicts mortality, and stratifies 
patients into correct risk categories over estab-
lished risk factors of this disease including cardiac 
involvement, cardiobiomarkers, and hypotension. 
Overall, these findings provide proof of concept on 
the clinical importance of assessing peripheral reac-
tive vasodilation in AL, thus setting the stage for 
further investigation of its utility as a biomarker in 
clinical practice. Finally, this study opens the field 
for the investigation of peripheral reactive vasodila-
tion in diseases characterized by hypotension and 
autonomic dysfunction.
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derivation cohort, AL patients were followed for all-cause mor-
tality. Events were confirmed by inspection of medical records 
or death certificate. To maximize diagnostic accuracy, in all 
patients, a strict institutional protocol regarding diagnosis, initial 
evaluation, treatment, and follow-up was applied.16,17
To assess differences in vascular characteristics attrib-
uted to the disease, AL patients from the prospective deriva-
tion cohort were matched with control subjects for age, sex, 
cardiovascular disease (CVD), risk factors, and coronary artery 
disease, aiming to minimize bias from factors known to affect 
FMD.18–20 We applied a hierarchical matching process, in a 1:k 
(maximum k, 7) ratio by using a greedy matching algorithm 
of the nearest neighbor for age and sex.21 Sex was matched 
exactly while the caliper for age enabled matching within a 
range of 2 years. Subsequently, estimated glomerular filtra-
tion ratio stage, coronary artery disease, diabetes mellitus, 
smoking, and hyperlipidemia were matched in a hierarchical 
order as described in Methods in the Online Data Supplement. 
This method resulted in almost perfect match for age, sex, 
and estimated glomerular filtration ratio, and close simulation 
for smoking, diabetes mellitus, and coronary artery disease as 
depicted in Table 1. To assess the impact of CVD risk factors 
on differences in vascular function between cases and con-
trols irrespective of age and sex, we additionally performed 
a triple 1:1 matching among (1) AL patients, (2) age- and 
sex-matched healthy controls without any cardiovascular risk 
factors or disease (ideal cardiovascular risk profile), and (3) 
controls matched for age, sex, and risk factors. Accordingly, 23 
triplets of subjects with the same age and sex were derived. In 
addition, a group of young (<40 years) healthy adults with ideal 
cardiovascular risk profile were recruited as positive controls. 
All control subjects were retrospectively recruited from an FMD 
Table 1. Characteristics of the Amyloidosis Population and of the Age-, Sex-, and Risk Factor–Matched 
Population
Parameters AL (n=115) Matched (n=115) P Value
Age, y 64.4±10.2 64.3±10.1 0.938
Sex (male), n (%) 62 (53.9) 62 (53.9) 0.999
Diabetes mellitus, n (%) 14 (12.2) 21 (18.3) 0.189
Hyperlipidemia, n (%) 50 (43.5) 69 (60.0) 0.009
Smoking, n (%) 18 (15.7) 23 (20.0) 0.371
Arterial hypertension, n (%)* 45 (39.1) 68 (59.1) 0.002
eGFR stage, n (%) 0.288
 Stage 1 36 (31.3) 26 (22.6)  
 Stage 2 27 (23.5) 33 (28.7)  
 Stage 3A 18 (15.7) 15 (13.0)  
 Stage 3B 13 (11.3) 5 (4.35)  
 Stage 4 8 (6.96) 6 (5.22)  
 Stage 5 13 (11.3) 6 (5.22)  
History of coronary artery disease, n (%) 12 (10.4) 14 (12.2) 0.659
SBP, mm Hg 123.7±22.5 132.0±20.9 0.005
Orthostatic hypotension, n (%) 37 (32.2) 0 (0) …
DBP, mm Hg 72.2±10.2 75.0±10.3 0.041
Baseline brachial diameter, mm/m2 2.22±0.41 2.31±0.40 0.101
Baseline flow stimulus, cm/s 7.46±4.85 7.58±6.18 0.876
Postocclusion hyperemic flow stimulus, cm/s 20.7±11 23.2±12.6 0.121
Shear stress, dyn/cm2 5.35±3.7 5.04±4.19 0.560
FMD (%) 4.00 (1.92–6.06) 2.32 (0.961–4.55) 0.004† (0.006)‡
Allometrically scaled FMD, % 1.78±1.53 0.99±2.68 0.005
Presence of any carotid plaque, n (%) 57 (49.6) 63 (54.8) 0.428
Presence of femoral plaque, n (%) 45 (39.1) 39 (33.9) 0.238
Presence of any plaque, n (%) 69 (60) 68 (59.1) 0.957
AL-specific treatment, n (%)
 Alkylator/steroid-based regimens, n (%) 17 (14.8)   
 Proteasome inhibitors or lenalidomide-based regimens, n (%) 98 (85.2)   
All continuous and dichotomous variables are described as mean±SD (except FMD where median [interquartile range] is provided) and n 
(%), respectively. P values are derived from independent samples t test and χ2 test for nominal variables. AL indicates light-chain amyloidosis; 
DBP, diastolic blood pressure; eGFR, estimated glomerular filtration ratio; FMD, flow-mediated dilatation; and SBP, systolic blood pressure.
*History of hypertension before diagnosis of AL.
†P value corresponds to the comparison of FMD values after logarithmic transformation or inverse rank normalization.
‡Baseline brachial artery diameter is normalized for body surface area.
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registry of 1071 subjects examined in our laboratory with vari-
ous prevalence of traditional risk factors, renal dysfunction, and 
CVD as described in Online Table I. Although these subjects 
were retrospectively included in the study, FMD registry was 
recruited during the same period (2008–2018) of the prospec-
tive AL cohorts, using the same methods for documentation of 
descriptive characteristics and vascular assessment.
To explore mechanisms and to validate our prospective sur-
vival results, we recruited 4 additional AL populations: (1) from 
2016 to 2017, 26 consecutive AL patients and 30 healthy con-
trol subjects with normal lung functional tests were recruited 
for exhaled NO and FMD assessment (exhaled NO cohort); (2) 
from March to November 2018, 19 consecutive AL patients 
and 10 young healthy volunteers were recruited for assess-
ment of brachial artery reactivity by cold pressor test (CPT) and 
of FMD (CPT cohort); (3) a prospective validation AL cohort 
of 55 newly diagnosed untreated patients who were consecu-
tively recruited from 2015 to 2018 from our Department and 
followed for all-cause mortality; (4) aiming to estimate associa-
tions between hematologic response and post-AL treatment 
effect FMD changes, we further analyzed data on 15 patients 
from the derivation cohort (recruited between December 2007 
and December 2009) with available FMD measurements 
at baseline (before treatment initiation) and 6 to 12 months 
post-treatment (prospective observational cohort) as described 
in Methods in the Online Data Supplement. Exclusion crite-
ria of the study are depicted in Methods in the Online Data 
Supplement. A flowchart illustrating enrolled cohorts and 
recruitment procedures in our study is provided in Figure 1.
This was a prospective noninterventional study, approved 
by the Institutional Review Board of the Department of Clinical 
Therapeutics, National and Kapodistrian University of Athens 
(Local Ethics Committee Approval reference No. 6.12.09.2008), 
and conducted in full compliance with Health Insurance Portability 
and Accountability Act and the principles of Good Clinical Practice 
and the Declaration of Helsinki. All patients gave written informed 
consent before their participation in the study.
FMD and Carotid and Femoral Ultrasound
A detailed description of the vascular studies is provided in the 
Online Data Supplement. In both prospective cohorts, during ini-
tial evaluation visit and before initiation of any chemotherapy or 
steroids, a series of vascular studies were performed. Reactive 
vasodilatation was assessed by FMD. FMD was measured using 
high-resolution ultrasonography (14.0-MHz multifrequency linear 
array probe, Vivid 7 Pro; General Electric Healthcare, Milwaukee, 
WI). In the derivation cohort, FMD was measured in the right bra-
chial artery of each subject offline on ECG R wave by acquir-
ing an average of 3-diameter measurements at baseline and the 
maximum diameter from a series of continuous manual measure-
ments taken every 15 seconds after cuff deflation (post-5 min-
utes of ischemic inflation at the level of antebrachium) for a time 
period of 90 seconds. FMD was calculated as described previ-
ously.22 In the validation, exhaled NO, and CPT cohorts, brachial 
artery was continuously acquired by ECG gating on R wave for 
30 seconds at baseline and for 120 seconds after cuff defla-
tion. Diameter was measured offline using dedicated automatic 
border detection software (Medical Imaging Applications LLC) 
as described previously.23 Aiming to use a second approach to 
correct FMD results for baseline brachial artery diameter, we 
also calculated an allometrically scaled FMD that takes into 
consideration more accurately differences in baseline diameter 
of brachial artery.24 Nitrate-dependent vasodilation was not mea-
sured, for ethical reasons, to avoid nitroglycerin-induced serious 
adverse reactions in this group of patients with high prevalence 
of orthostatic hypotension (32.2%; Table 1). Most importantly, as 
explained in detail in the Online Data Supplement, autonomic and 
cardiac dysfunction, which are commonly met in patients with AL 
(40% and 67% in our population, respectively), may exacerbate 
serious and unpredictable adverse effects by nitroglycerin. In the 
derivation cohort, high-resolution ultrasound was performed in 
the carotid and femoral arteries using similar equipment to that 
for FMD measurement. The presence and number of peripheral 
plaques were assessed as described previously.25,26
Additional Assessment of Underlying 
Mechanisms Associated With Increased  
FMD in AL
Because of the lack of validated animal models and unaccept-
ably high risk of adverse reactions from performing nitroglyc-
erin-induced vasodilation in patients with AL, implementation 
of direct experimental investigation of increased FMD in AL 
patients was not feasible. Instead, we focused on the follow-
ing approaches: (1) we evaluated brachial artery diameter 
responses to sympathetic stimulation induced by the CPT 
cohort and (2) we measured markers of NO bioavailability and 
associated nitrosative stress because FMD is known to be at 
least partly mediated by NO bioavailability7,8 (prospective and 
exhaled NO cohort). Detailed rationale and methods used for 
this approach are provided in the Online Data Supplement.
Cold Pressure Test
Brachial artery diameter reaction to CPT was used as a vali-
dated method to measure vascular response during and after 
sympathetic stimulation in humans.27
Circulating Markers of NO Pathway 
Measurements
Plasma levels of nitrites (Cayman Nitrate/Nitrite Colorimetric 
Assay Kit 780001) as an index of total NO availability,28 cyclic 
GMP (cGMP; Direct cGMP ELISA kit: ADI-900-013; Enzo Life 
Sciences) as a critical downstream molecule in the signaling 
cascade of NO in vascular smooth muscle cells,29 and 3-nitro-
tyrosine (NTY; 3-Nitrotyrosine ELISA Kit: No. K4158-100; 
BioVision) as an index of nitrosative stress30 were measured.
Exhaled Alveolar NO
To further explore possible associations between NO bioavailabil-
ity and increased FMD, exhaled alveolar NO (MasterScreen Body, 
Jaeger, Germany) was measured as an indicator of the endog-
enously produced NO levels in the pulmonary vasculature and 
as a second marker of basal total NO release from vasculature.31
Statistical Methods
Normal distribution of all continuous variables was tested with 
the parametric test Shapiro-Wilk and graphically assessed by 
histograms and P-P plots. Differences between controls and 
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cases were assessed by independent samples t test or 1-way 
ANOVA with post hoc comparisons corrected by the Dunnett 
method for continuous variables and χ2 test for nominal variables. 
FMD did not follow the normal distribution in histograms and 
quantile-quantile plots and was tested after natural log trans-
formation or inverse rank normalization. For FMD (in logarithmic 
scale), we used linear regression analysis to further compare the 
2 groups after adjusting for potential confounders: (1) traditional 
risk factors, that is, systolic and diastolic BP, hypertension, hyper-
lipidemia, smoking, and diabetes mellitus; (2) baseline brachial 
artery diameter and postocclusion hyperemic flow stimulus; and 
(3) the presence of peripheral plaque or coronary artery disease.
Cox proportional-hazards models were used to examine the 
association between a series of baseline predictors and the 
main end points (ie, early mortality at 6 months and overall mor-
tality) of the study. We tested all available predictors of survival 
in AL as proposed in medical literature,3 as well as variables with 
biological plausibility (age and sex) in univariate Cox regression 
models (Statistical Methods in the Online Data Supplement). 
Those presenting a signal or significant association (P<0.1) in 
univariate models were tested in the multivariable Cox models 
(Statistical Methods in the Online Data Supplement) to identify 
independent parameters for survival end points. To assess the 
functional form of the association between all-cause mortality 
and continuous FMD, we implemented restricted cubic splines 
with 3 knots.32 Subsequently, we aimed to analyze the prognos-
tic value of FMD using a clinically relevant cutoff. For this pur-
pose, the cutoff point for FMD (ie, 4.5%) was derived using 2 
statistical approaches. First, we determined the optimal cut point 
of FMD predicting mortality under survival settings using the 
method proposed by Contal and O’Qingley.33 We further con-
firmed this cut point by receiver operating characteristic anal-
ysis and selection of the maximum product of sensitivity and 
specificity according to the Liu method.34 In addition, we sought 
to assess the incremental value of FMD over the best predic-
tive model for reclassification improvement toward the survival 
end points by calculating the continuous Net Reclassification 
Index (NRI)35 and the integrated discrimination improve-
ment, as described in detail in the Online Data Supplement. 
Statistical analysis was performed by STATA package, version 
11.1 (StataCorp, College Station, TX). Regarding our secondary 
hypothesis exploring the association of increased FMD in AL 
patients with markers of NO metabolism, P values were cor-
rected by the Holm-Bonferroni method36 to control the family-
wise error rate. We deemed statistical significance at a=0.05.
RESULTS
Comparisons of FMD Between AL Patients and 
Matched Controls
Descriptive characteristics of AL and control groups 
are depicted in Table 1 and Online Tables I through III. 
Mean age in AL patients was 64.4±10.2 years and prev-
alence of female sex was 46.1%, which did not differ 
from controls. Prevalence of hyperlipidemia and hyper-
tension in AL patients was lower than controls, whereas 
prevalence of diabetes mellitus, smoking, and coronary 
artery disease did not differ between groups. FMD was 
Figure 1. Flowchart of study design.  
AL indicates light-chain amyloidosis; CPT, cold pressure test; CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factor; 
and FMD, flow-mediated dilatation.
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significantly higher in AL patients compared with non-
AL–matched controls (n=115 per group; P=0.004; 
Table 1) and comparable to the FMD registry (Figure 2A). 
This difference was confirmed with allometrically scaled 
FMD (Table 1). Baseline and hyperemic flow stimulus, 
baseline brachial diameter, and shear stress were simi-
lar between AL patients and matched controls (Table 1). 
Importantly, FMD in AL group was higher in compari-
son to matched controls after adjustment for baseline 
brachial artery diameter and postocclusion hyperemic 
flow stimulus (P=0.005). After adjustment for param-
eters known to affect FMD7,37 (ie, systolic and diastolic 
BP, hypertension, smoking, hyperlipidemia, and diabetes 
mellitus), this difference did not change (P=0.017). This 
difference in FMD remained significant after controlling 
for the presence of peripheral atherosclerotic plaque or 
coronary artery disease (P=0.008).
The triple 1:1-matched analysis (n=23 per group) 
revealed that FMD in AL patients (4.35% [2.04–5.26]) 
was significantly higher than their age-, sex-, and risk 
factor–matched counterparts (2.17% [0.82–3.64]; 
P=0.043), was comparable with their healthy age- and 
sex-matched controls (4.17% [3.46–7.6]), and lower 
than the ideally healthy group of young adults (5.86% 
[4.65–7.87]; P=0.004; Figure 2B).
Prognostic Importance of Vascular Markers 
in Patients With AL in the Derivation and 
Validation Cohort
After a median follow-up of 45 months, 48 patients died 
in the derivation cohort (41.7%). Early death is a common 
complication of AL3: 17 deaths (35%) occurred within 
the first 6 months and 27 deaths (56%) until the end 
of the first year of follow-up. In univariate analysis, FMD 
as a continuous variable was associated with higher risk 
of death (hazard ratio [HR], 1.08; 95% CI, 1.01–1.15; 
P=0.023), indicating that increasing FMD could be a 
marker of high-risk disease. In the smoothing plot of log 
HR versus the FMD (Online Figure I), we observed a 
curvilinear association between FMD and mortality that 
suggested the possible existence of a change point in 
the dose-response phenomenon. The estimated change 
point assessed by the Contal and O’Qingley method (log-
rank test statistic, 11.1; P=0.007) and receiver operat-
ing characteristic analysis (area under the curve, 0.650; 
P=0.004), as described in the statistics section, was a 
cutoff value of FMD ≥4.5%. As shown in Figure 3A, FMD 
≥4.5% was associated with increased risk of death and 
shorter survival (log-rank test, P=0.001). More specifi-
cally, the median overall survival of AL patients with FMD 
≥4.5% was 21.3 months versus 71 months for patients 
with FMD <4.5%. A secondary analysis revealed that 
early mortality (within the first 6 months) was 44.4% for 
Figure 2. Flow-mediated dilatation (FMD) in light-chain 
amyloidosis (AL) patients and control populations.  
A, FMD was increased in 115 AL patients compared with age-, 
sex-, and cardiovascular risk factors–matched controls (n=115) 
but not to the total unmatched FMD registry (n=1071). B, In 23 
triplets with different levels of matching, FMD in AL patients was 
increased in comparison to age-, sex-, and risk factor (RF)-matched 
controls, comparable to age- and sex-matched healthy adults 
with ideal cardiovascular risk profile and lower than young healthy 
controls with ideal cardiovascular risk profile. P values are derived 
from ANOVA with post hoc pairwise comparisons corrected by the 
Dunnett method. Bars represent median values and spikes SE, 
respectively. AL patients were matched 1:1 with subjects from the 
FMD registry using a hierarchical model by age, sex, and estimated 
glomerular filtration ratio stage and subsequently diabetes mellitus, 
coronary artery disease, smoking, and hyperlipidemia. Matching was 
not performed for arterial hypertension because low blood pressure 
is a manifestation of AL.
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subjects with FMD ≥4.5% versus 17.8% for AL patients 
with FMD <4.5% (log-rank test, P=0.003; Figure 3B).
High Mayo stage, low BP <100 mm Hg, and nerve 
involvement consisted the best prognostic model for 
mortality in the derivation cohort (Online Table IV). FMD 
≥4.5% remained an independent prognostic factor asso-
ciated with higher risk of death after adjusting for these 
factors (adjusted HR, 2.11; 95% CI, 1.17–3.82; P=0.013; 
Table 2). Further adjustment for AL-specific treatment did 
not attenuate this association (adjusted HR, 2.11; 95% CI, 
1.17–3.83; P=0.013). Increased FMD was still indepen-
dently associated with mortality (adjusted HR, 2.11; 95% 
CI, 1.13–3.95; P=0.019) after additionally controlling for 
preocclusion brachial artery diameter, peak hyperemic 
flow, and shear stress (Table 2). In contrast, hyperemic 
flow velocity or baseline brachial artery diameter were not 
related with mortality in the AL derivation cohort (P>0.1 
for both). Age and sex are strong determinants of FMD,18 
whereas decreased FMD is associated with atheroscle-
rosis.19 After additional adjustment for age, sex, presence 
of subclinical and coronary atherosclerosis, FMD ≥4.5% 
remained an independent prognostic factor associated 
with higher risk of death (adjusted HR, 2.25; 95% CI, 
1.20–4.20; P=0.011; Table 2). Increased FMD was also 
an independent predictor of mortality at 6 months after 
adjustment for the best prognostic model including Mayo 
stage and nerve involvement (adjusted HR, 4.36; 95% 
CI, 1.41–13.5; P=0.010; Online Table V). These results 
did not change after adjustment for NT-proBNP (N-ter-
minal pro-B-type natriuretic peptide; HR, 2.42; 95% CI, 
1.35–4.35; P=0.003), high-sensitive Troponin T (hsTnT; 
HR, 2.35; 95% CI, 1.26–4.39; P=0.007), or both (HR, 
2.35; 95% CI, 1.25–4.40; P=0.007) instead of Mayo 
stage, even after additionally controlling for low systolic 
BP and nerve involvement (P<0.05 for all 3 models). In 
a sensitivity analysis, restrained to AL patients with heart 
involvement (n=77), increased FMD was still an indepen-
dent predictor of mortality (HR, 1.92; 95% CI, 1.0–3.61; 
P=0.045). Finally, the association of increased FMD 
≥4.5%, with all-cause mortality in AL, was confirmed in 
the validation AL cohort (n=55; HR, 4.2; 95% CI, 1.45–
12.3; P=0.008 and P=0.004 by log-rank test; Figure 3C).
Reclassification Value of FMD as a Prognostic 
Factor in Patients With AL
FMD ≥4.5% correctly reclassified both high-risk AL 
patients who experienced the event (NRI among event 
subjects, 20.8%) and lower risk subjects who survived 
until the end of the follow-up (NRI among nonevent 
subjects, 40.3%) over the best prognostic model. Thus, 
a substantial fraction of AL patients would be reclassi-
fied into the correct risk category if FMD was addition-
ally taken into consideration (overall NRI, 0.61; P=0.001; 
Table 3). Similarly, increased FMD conferred significant 
reclassification value for early mortality at 6 months as 
shown in Table 3 (overall NRI, 0.579; P=0.045) and on 
top of cardiac biomarkers (overall NRI, 0.633; P=0.002 
and NRI, 0.561; P=0.003 over NT-proBNP and hsTnT, 
respectively). In addition, FMD ≥4.5% significantly 
increased integrated discrimination improvement over 
the best prognostic model for both early mortality and 
overall survival (Table 3).
Figure 3. Kaplan-Meier curves for probability of survival in 
light-chain amyloidosis (AL) patients according to flow-
mediated dilatation (FMD) values ≥4.5% or <4.5%.  
In patients with increased FMD (≥4.5%) as compared with those 
with lower levels (<4.5%), Kaplan-Meier curves show inferior overall 
survival (A) until the end of follow-up (original AL cohort), (B) at 6-mo 
follow-up (original AL cohort), and (C) until the end of follow-up in the 
validation cohort. P was calculated by log-rank test.
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Differences Between Low- and High-Risk AL 
Patients According to FMD
As shown in Online Table VI, patients with FMD ≥4.5% 
had more often heart involvement (79.6% versus 
57.6%; P=0.013), increased baseline levels of hsTnT 
(P=0.007) and NT-proBNP (P=0.023), and thus had 
more often advanced Mayo stage disease (36.7% ver-
sus 18.2% for stage III; P=0.033) than patients with 
FMD <4.5%.
Sympathetic Stimulation by CPT
Patients with AL (n=19) showed increased and sustained 
vasodilation in response to sympathetic stimulation as 
assessed by CPT when compared with healthy controls 
(n=10; 4.39±2.52% versus 2.62±1.31% at T1, during CPT, 
and 4.43±3.23% versus 1.59±1.95% at T2, 3 minutes after 
CPT withdrawal, respectively; P<0.05 for both; Figure 4A 
and 4B). A significant group interaction was observed at T2, 
indicating that CPT-induced vasodilatation was prolonged in 
Table 2. Multivariable Analysis of Factors Affecting Survival in 115 Patients With Light-Chain Amyloidosis
Core Multivariable Extended Multivariable Model 1* Extended Multivariable Model 2†
 HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Disease-specific parameters
 Mayo stage       
  Stage I       
  Stage II–IIIA 3.56 (1.20–10.6) 0.022 3.75 (1.23–11.4) 0.020 3.42 (1.10–10.6) 0.034
  Stage IIIB 9.36 (2.60–33.6) <0.001 9.44 (2.46–36.2) 0.001 9.16 (2.36–35.6) 0.001
 Nerve involvement 3.59 (1.90–6.77) <0.001 4.16 (2.10–8.23) <0.001 3.55 (1.79–7.06) <0.001
 SBP (≤100 mm Hg) 2.19 (1.14–4.20) 0.019 2.62 (1.24–5.53) 0.012 2.34 (1.16–4.77) 0.018
FMD-specific parameters
 FMD ≥4.5% or <4.5% 2.11 (1.17–3.82) 0.013 2.11 (1.13- 3.95) 0.019 2.25 (1.20–4.20) 0.011
 Shear stress   0.919 (0.807–1.05 0.207   
 Baseline diameter   0.880 (0.653–1.19) 0.207   
 Hyperemic flow   0.995 (0.961–1.03) 0.765   
Atherosclerosis parameters
 Coronary artery disease     1.32 (0.500–3.50) 0.574
 Presence of atherosclerotic plaque     1.10 (0.537–2.24) 0.799
Demographics
 Age     1.01 (0.977–1.04) 0.620
 Sex     0.997 (0.476–2.09) 0.994
DBP indicates diastolic blood pressure; FMD, flow-mediated dilatation; HR, hazard ratio; and SBP, systolic blood pressure.
*In the extended multivariable model 1, the association of FMD with all-cause mortality was further adjusted for FMD-specific parameters including shear 
stress, baseline brachial diameter, and hyperemic flow.
†In the extended multivariable model 2, age, sex, presence of coronary artery disease, and presence of subclinical atherosclerosis as possible confounders 
affecting vascular reactivity were included.
Table 3. Reclassification Value of Flow-Mediated Dilatation Over the Best Predictive Model for Early and Overall All-
Cause Mortality in 115 Light-Chain Amyloidosis Patients
Continuous NRI IDI
Subjects Correctly 
Reclassified, %
Subjects Incorrectly 
Reclassified, %
Net Reclassification 
Gain, % Overall NRI (SE) P Value IDI (SE) P Value
All-cause mortality at the end of the follow-up
 Events (n=48) 29 (60.4%) 19 (39.6%) 20.8 0.61 (0.189)* 
[0.231–0.992]
0.001 3.6 (1.8) 0.044
 Nonevents (n=67) 47 (70.1%) 20 (29.8%) 40.3
Early mortality at 6 mo
 Events (n=17) 13 (76.4%) 4 (23.5%) 52.9 0.579 (0.29) 
[0.095–1.06]
0.045 6.5 (3.0) 0.031
 Nonevents (n=98) 51.5 (52.5%) 46.5 (47.5%) 5.0
Best prognostic model for all-cause death at the end of the follow-up: Mayo stage (stage I vs II–IIIA vs IIIB), nerve involvement, and systolic blood pressure 
≤100 mm Hg. Best prognostic model for early mortality: Mayo stage (stage I vs II–IIIA vs IIIB) and nerve involvement. IDI indicates integrated discrimination 
improvement; and NRI, net reclassification index.
*95% bias-corrected bootstrap CIs.
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the AL group (P for interaction, 0.023). Importantly, in AL 
patients but not in controls, there was a significant correla-
tion of FMD with maximum percentage vasodilation by CPT 
(Figure 4C through 4F). Patients with AL and controls did 
not differ in respect to baseline serum levels and changes in 
noradrenaline as shown in Online Table VII.
NO Pathway in AL
Characteristics of the AL patients with available blood 
samples to measure markers of NO pathway did not 
differ from the rest of the AL population (Online Table IX). 
Circulating levels of cGMP were increased (P<0.001) in 
the AL group, whereas nitrite and NTY levels did not dif-
fer compared with the control group (Figure 5A through 
5C). Exhaled alveolar NO was increased in AL patients 
(n=26) as compared with healthy individuals (n=30; 
P<0.001; Figure 5D). When this population was ordered 
in 3 groups (ie, controls, AL patients with low FMD 
<4.5% and high FMD ≥4.5%), cGMP and exhaled alveo-
lar NO gradually increased across ascending groups 
(P<0.001 for both; Figure 5G and 5H). These results 
Figure 4. Flow-mediated dilatation (FMD) and autonomic function in light-chain amyloidosis (AL).  
Cold pressure test (CPT) changes at sympathetic (A) and 3-min postsympathetic stress (B) are increased in AL patients (n=19) in comparison to controls 
(n=10). CPT changes at sympathetic and postsympathetic stress are related to baseline FMD in AL patients (C and D) but not in control subjects (E 
and F). P values in A and B are derived from independent samples t test. P values in C–F are derived from Pearson correlation test. Horizontal wide lines 
represent mean (A and B) values and error bars SE, respectively. Postsympathetic stress was assessed 3 min after removal of cold stimulus.
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Figure 5. NO pathway in light-chain amyloidosis (AL).  
Differences in plasma levels of (A) nitrites, (B) 3-nitrotyrosine (NTY), (C) cyclic GMP (cGMP), and (D) exhaled alveolar NO between controls 
and AL patients of the prospective (A–C) and the exhaled NO (D) cohorts. E–H are derived from the same research population as A–D but 
after discriminating AL patients according to low (<4.5%) and high (>4.5%) flow-mediated dilatation (FMD). I–K, Only AL patients with heart 
involvement are considered and compared according to FMD <4.5% or >4.5%. P values denote difference from controls as derived from 
independent samples t test (A–D and I–K) and ANOVA with post hoc pairwise comparisons corrected by the Dunnett method (E–H). Horizontal 
wide lines and error bars represent mean±SE, respectively.
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did not materially change after adjusting for smoking and 
estimated glomerular filtration ratio stage, which signifi-
cantly differed between controls (n=24) and AL patients 
(n=57; Online Table X).
In the high-risk group of patients with heart involve-
ment, cGMP and NTY levels were significantly increased 
in patients with increased FMD ≥4.5% as compared with 
those with FMD <4.5% (Figure 5I through 5K). These 
findings were replicated after inverse rank normalization. 
In an exploratory analysis, FMD ≥4.5% remained signifi-
cantly associated with increased all-cause mortality inde-
pendently of cGMP and NTY (n=54; HR, 3.65; 95% CI, 
1.58–8.4; P=0.002).
Changes of FMD After Treatment: a Prospective 
Analysis
In a subgroup of 15 patients with available pre- and 
posttreatment FMD measurements, persistently low 
posttreatment FMD (<4.5%) was associated with better 
response to treatment as compared with increased post-
treatment FMD (P=0.021 by ordinal Kendal Tau test; 
Online Figure III). Persistently low FMD was also associ-
ated with lower mortality (P=0.026; Online Table XII).
DISCUSSION
To our knowledge, this is the first study that prospectively 
evaluates a dynamic marker of peripheral vasodilation in 
patients with systemic AL, a disease that is often accom-
panied by autonomic dysfunction, orthostatic hypoten-
sion, and low resting BP,4,38 which are all associated 
with inferior survival.3,39 Given that under conditions of 
decreased BP or low sympathetic activity, FMD is aug-
mented,11–14 we hypothesized that this dynamic marker 
of reactive vasodilation could confer clinically relevant 
prognostic value in patients with AL. Our findings are 
supporting this hypothesis, revealing 3 major implica-
tions: first, they indicate that arterial vasodilatory function 
is relatively augmented in a clinically important degree in 
AL; second, they provide a measurable marker as an indi-
cator of increased reactive arterial dilatation in patients 
with AL; and third, suggest that FMD could serve as 
a novel biomarker for risk stratification of AL patients. 
Furthermore, in a secondary analysis aiming to explore 
the underlying mechanisms of our findings, we observed 
vascular autonomic dysfunction and multiple signals of 
augmented or preserved levels of systemic markers of 
NO pathway activity associated with increased FMD.
Systemic AL is a disease with high rates of early 
mortality due to cardiovascular complications.3,40 The 
impact of the severity of cardiac amyloidosis in survival 
is so strong that disease staging is based on cardiac 
biomarkers. However, low BP (<100 mm Hg) was also 
found to predict mortality among patients at higher risk 
(ie, those at Mayo stage III).3 Interestingly, in the cur-
rent study, increased FMD was a predictor of mortality 
irrespective of the best prognostic model that included 
both advanced Mayo stage (stage IIIB) or NT-proBNP 
and troponin and low BP. The strongest association was 
observed with early mortality, with FMD ≥4.5%, increas-
ing the odds for death by a factor of >4. Furthermore, 
this association remained significant even after adjust-
ing for the presence of atherosclerosis, suggesting that 
increased reactive vasodilatation in AL patients may 
offset assumed benefits from the traditionally accepted 
healthy vascular profile reflected by increased FMD.5–7 
In addition, increased FMD substantially improved risk 
stratification by correctly reclassifying AL patients into 
higher or lower risk categories for early and late mortal-
ity. Importantly, our prognostic findings were confirmed 
in a temporal validation cohort with comparable clinical 
and vascular characteristics. As expected, patients from 
the validation cohort where followed for a shorter period. 
However, there was a clear signal of association between 
FMD ≥4.5% and mortality because of the known high 
incidence of early mortality in AL.3
Despite technical difficulties in FMD measurement, 
such as long learning curve, as well as lack of uni-
versally accepted reference values and standardized 
protocols,7,37,41 these results indicate that FMD fulfills 
epidemiological criteria for further evaluation as a novel 
biomarker in AL and may be of clinical utility for a risk-
guided treatment approach. Whether contemporary 
treatment for amyloidosis may affect FMD and, more 
importantly, whether such response to treatment would 
improve outcome in these patients is unknown. To that 
direction, our analysis of prospective data suggests that 
AL patients who achieve a hematologic response may 
retain low posttreatment FMD. Interestingly, despite the 
limited sample size, there was also a signal for improved 
survival associated with this FMD pattern. Several novel 
treatment regimens such as proteasome inhibitors and 
lenalidomide-based regimens may directly inhibit endo-
thelial dilatation,42,43 but whether they exert any effect on 
FMD in AL patients is unknown. Further research is war-
ranted to explore the clinical value of FMD response to 
treatment of AL, as well as that of targeting pathways 
related with increased disease-specific FMD. In addi-
tion, these are the first epidemiological data indicating 
that increased reactive vasodilation in a selected popula-
tion with hypotension is associated with mortality. Given 
that orthostatic hypotension has been shown to predict 
mortality in the general population,44 our findings set the 
grounds for elucidating the role of FMD in identifying 
high-risk patients with conditions presenting low BP.
Subsequently, we explored possible mechanisms 
related to increased FMD in AL. Although, previous evi-
dence has implicated AL with microvascular endothelial 
dysfunction,45 FMD is not associated with microvascular 
endothelial function in humans.46 Thus, our findings may 
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not be relevant to microvascular dysfunction. Further-
more, despite that our NO results cannot prove causality 
because of their cross-sectional nature and, therefore, 
cannot exclusively explain the prognostic utility of FMD 
in amyloidosis, they suggest that increased activity of NO 
as denoted by high cGMP plasma levels and exhaled NO 
in AL patients may contribute to increased reactive vaso-
dilation. Notably, we found cGMP plasma levels markedly 
elevated by a factor of >10 as compared with controls, 
which was disproportionally high in relation to nitrite 
plasma levels in these patients. Although circulating 
cGMP may not substitute local levels and, therefore, may 
not directly reflect vascular smooth muscle cell reactivity 
to NO, these findings are suggestive of increased NO 
sensitivity of GC (guanylyl cyclase), the enzyme regulat-
ing downstream production of cGMP,29 which might lead 
to enhanced downstream production of cGMP possibly 
contributing to increased FMD in AL patients.29–31 Indeed, 
in AL patients with cardiac involvement comprising the 
majority of our AL population (67%), we found cGMP 
levels to be associated with increased FMD. Accordingly, 
increased or sustained NO availability may be detrimen-
tally associated with hemodynamic vasodilatory indices 
in other diseases such as liver cirrhosis.47 In support, 
overdilatation, expressed as markedly augmented FMD, 
has been previously reported in conditions related to 
orthostatic hypotension or lowering of sympathetic activ-
ity such as cirrhosis and vasovagal syncope.9,10,12 Hypo-
tension in AL4,38 has been attributed to markedly reduced 
autonomic modulation in the heart and the peripheral 
vasculature mainly through sympathetic denervation.4,48 
Our findings regarding the underlying mechanisms are 
in agreement with studies where increased cGMP was 
found in conditions with cardiac dysautonomia.49 Aug-
mented cGMP can be linked with altered nNOS (neuronal 
NO synthase) activity, which could modify both NO bio-
availability and NO-cGMP coupling at the level of nerve 
endings and peripheral autonomic ganglia in patients 
with AL49. Increased cGMP levels have been proposed 
to decrease neurotransmission in sympathetic neurons, 
whereas increased NO bioavailability in parasympa-
thetic neurons has been shown to facilitate acetylcho-
line release.49 It is well known that FMD is responsive to 
sympathetic stimulation or inactivation.13,14,50 Accordingly, 
we found that FMD in AL patients was strongly associ-
ated with higher brachial artery dilatation in response to 
sympathetic stimulation compared with healthy controls. 
This reaction may be regarded as paradoxical, as it is 
contrasted to traditionally observed vasoconstriction in 
patients with atherosclerotic disease.51
Another point of interest is that NTY in AL was associ-
ated with increased FMD. In individuals without AL, nitro-
tyrosine is considered a marker of peroxynitrite load and 
nitrosative stress and is expected to be inversely associ-
ated with FMD.52 Although there are no specific data in 
AL, in other β-sheet amyloidosis such as Aβ (amyloid-β) 
deposition and transthyretin amyloidosis, nitrosylation of 
tyrosine may be directly involved in disease pathogen-
esis.53–55 Thus, our unexpected observation of increased 
NTY levels in high-risk AL patients with elevated FMD 
may reflect a parallel disease processes with nitroty-
rosine being involved in amyloidosis progression. On 
the contrary, recent experimental evidence indicates 
that nitrotyrosine may induce unexpected vasodilatory 
response to β-adrenergic agonists through blocking of 
β2 adrenergic receptor internalization at nerve endings.56 
Interestingly, CPT may induce vasodilation through stim-
ulation of postjunctional β2 adrenoceptors51 and could, 
therefore, be enhanced by increased NTY local concen-
trations. Thus, the effect of local concentrations of NTY 
on paradoxical vasodilation by CPT observed in our AL 
population should be further explored.
Overall, considering that hyperemic change during 
performance of FMD was similar in both groups of high 
and low FMD and that CPT showed similar to FMD par-
adoxical vasodilatory response in AL, our results point 
to the direction of a generalized conductance vascular 
abnormality, suggesting that these patients are incapable 
of vasoconstricting in response to sympathetic activation. 
Thus, FMD may be considered a cumulative marker of 
increased risk of death in AL that may predominantly 
integrate autonomic maladaptation of vascular function 
with sustained vasodilation. Whether increased NO and 
associated nitrosative stress is actively involved in this 
process merits further investigation. To this end, a sen-
sitivity analysis indicated that adjustment for cGMP and 
NTY levels did not affect the association of increased 
FMD with mortality. However, these survival results 
should be interpreted with caution because of the limited 
number of patients with available NO markers.
Certain limitations of our study should be acknowl-
edged. First, it should be clarified that this study provides 
for the first time proof of concept on the clinical impor-
tance of assessing peripheral reactive vasodilation in AL 
and does not suggest a biomarker for immediate clinical 
application. FMD is known to present relatively wide vari-
ability,7,37,41 both from a biological and technical point of 
view, which may hamper its validation as a biomarker in 
clinical practice. To address these methodological limita-
tions, we used a standardized strict FMD protocol, which 
is reflected by a reproducibility performance comparable 
to current literature,37 and statistically considered most 
parameters known to affect FMD to avoid residual con-
founding. Furthermore, confirmation of our survival results 
in a contemporary AL validation cohort indicates that 
FMD survival findings are reproducible in a single refer-
ence center setting. Thus, although FMD as a marker of 
endothelial dysfunction is not currently recommended for 
risk assessment in CVD because of its limited incremen-
tal value beyond existing biomarkers and risk scores, its 
use as a marker of reactive overdilation for wide clinical 
practice specifically in diseases related with autonomic 
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dysfunction and hypotension should be de novo consid-
ered. Such validation of FMD or of other markers of reac-
tive vasodilatation needs independent confirmation in 
several other studies and definition of normal and refer-
ence values using a reproducible and universally consis-
tent disease-specific methodology. Second, relatively low 
FMD values were found in the control group. This is not 
unexpected for 2 reasons: (1) we used the distal occlu-
sion approach because of methodological advantages 
over the proximal occlusion technique,7,57 which in gen-
eral yields lower FMD values58 and (2) control subjects 
were highly selected because of the matching process 
with AL cases and, therefore, presented at least similarly 
high prevalence of characteristics known to adversely 
affect FMD.18–20 Indeed, our unmatched and age- and 
sex-only–matched healthy control groups presented 
comparable or higher FMD values with AL cases rang-
ing closely to published literature.37,58 Thus, low FMD of 
our strictly matched controls may reflect a high CVD risk 
factor burden of their AL counterparts (101 of 115 sub-
jects had at least 2 CVD risk factors). AL patients in turn, 
despite their adverse cardiovascular profile, presented 
unexpectedly high FMD values, which were comparable 
to individuals with healthier CVD risk profile. These find-
ings support the presence of inherent mechanisms in AL 
adversely augmenting FMD as discussed above. Finally, 
it should be noted that, apart for the CPT experiment, 
we applied a retrospective control patient method using 
a prospectively recruited FMD registry. However, con-
trol subjects were examined in our laboratory during the 
same recruitment period of the derivation and validation 
AL cohorts, using the same methods for documentation 
of population characteristics, as well as for FMD assess-
ment. Finally, it should be acknowledged that with testing 
multiple potential mechanisms, there is the possibility of 
type I error attributable to multiple testing.
In conclusion, in patients with primary systemic AL, 
increased FMD was an independent predictor of all-
cause mortality over validated prognostic factors and 
improved risk stratification. Furthermore, we found evi-
dence of relatively increased reactive vascular dilata-
tion, which was mainly associated with altered vascular 
autonomic function. Importantly, prospective data sup-
port an association between hematologic response and 
posttreatment FMD changes. Thus, FMD merits further 
investigation as a possible novel noninvasive biomarker 
to assess risk of mortality in AL patients aiming to guide 
risk-based treatment. In addition, these are the first pro-
spective data providing a proof of concept that reactive 
overdilatation may identify high-risk patients in chronic 
hypotensive conditions.
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